biote Corp. continues to grow its network of certified hormone optimization practitioners and enhance its digital platform offerings, underpinning a dual revenue model of long-term service agreements and branded supplement sales. Recent quarterly results show progress toward profitability with break-even earnings reported in Q2 2026, supported by practitioner expansion and e-commerce supplement growth. However, the company faces ongoing legal risks and must manage leverage carefully in its pursuit of scale. Success depends on sustaining practitioner retention, growing digital engagement, and navigating regulatory scrutiny in a competitive healthcare services landscape.